|
Jiangsu Hengrui Medicine Co., Ltd. (600276.SS) Valoración de DCF
CN | Healthcare | Drug Manufacturers - General | SHH
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Jiangsu Hengrui Medicine Co., Ltd. (600276.SS) Bundle
¡Mejore su estrategia de inversión con la calculadora DCF (600276SS)! Explore datos financieros genuinos para Jiangsu Hengui Medicine Co., Ltd., ajuste las proyecciones y gastos de crecimiento, y visualice instantáneamente cómo estas modificaciones afectan el valor intrínseco de (600276SS).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 23,288.6 | 27,734.6 | 25,905.5 | 21,275.3 | 22,819.8 | 22,927.2 | 23,035.0 | 23,143.4 | 23,252.3 | 23,361.7 |
| Revenue Growth, % | 0 | 19.09 | -6.59 | -17.87 | 7.26 | 0.47053 | 0.47053 | 0.47053 | 0.47053 | 0.47053 |
| EBITDA | 6,681.2 | 7,377.3 | 5,021.1 | 4,683.2 | 5,540.4 | 5,546.6 | 5,572.7 | 5,598.9 | 5,625.3 | 5,651.8 |
| EBITDA, % | 28.69 | 26.6 | 19.38 | 22.01 | 24.28 | 24.19 | 24.19 | 24.19 | 24.19 | 24.19 |
| Depreciation | 645.8 | 475.2 | 540.7 | 644.2 | 793.9 | 599.8 | 602.6 | 605.5 | 608.3 | 611.2 |
| Depreciation, % | 2.77 | 1.71 | 2.09 | 3.03 | 3.48 | 2.62 | 2.62 | 2.62 | 2.62 | 2.62 |
| EBIT | 6,035.3 | 6,902.0 | 4,480.3 | 4,039.1 | 4,746.5 | 4,946.8 | 4,970.1 | 4,993.5 | 5,017.0 | 5,040.6 |
| EBIT, % | 25.92 | 24.89 | 17.29 | 18.98 | 20.8 | 21.58 | 21.58 | 21.58 | 21.58 | 21.58 |
| Total Cash | 13,563.4 | 16,432.7 | 18,721.2 | 17,871.2 | 20,845.2 | 16,741.6 | 16,820.4 | 16,899.5 | 16,979.0 | 17,058.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 5,434.8 | 8,175.7 | 6,883.9 | 8,341.5 | 6,134.9 | 6,670.9 | 6,702.3 | 6,733.8 | 6,765.5 | 6,797.3 |
| Account Receivables, % | 23.34 | 29.48 | 26.57 | 39.21 | 26.88 | 29.1 | 29.1 | 29.1 | 29.1 | 29.1 |
| Inventories | 1,606.8 | 1,778.1 | 2,402.7 | 2,450.6 | 2,314.0 | 2,028.8 | 2,038.3 | 2,047.9 | 2,057.6 | 2,067.2 |
| Inventories, % | 6.9 | 6.41 | 9.27 | 11.52 | 10.14 | 8.85 | 8.85 | 8.85 | 8.85 | 8.85 |
| Accounts Payable | 1,289.2 | 1,326.2 | 2,252.8 | 1,767.5 | 1,334.0 | 1,520.9 | 1,528.0 | 1,535.2 | 1,542.5 | 1,549.7 |
| Accounts Payable, % | 5.54 | 4.78 | 8.7 | 8.31 | 5.85 | 6.63 | 6.63 | 6.63 | 6.63 | 6.63 |
| Capital Expenditure | -561.4 | -554.3 | -1,664.6 | -1,992.2 | -1,483.8 | -1,224.4 | -1,230.1 | -1,235.9 | -1,241.7 | -1,247.6 |
| Capital Expenditure, % | -2.41 | -2 | -6.43 | -9.36 | -6.5 | -5.34 | -5.34 | -5.34 | -5.34 | -5.34 |
| Tax Rate, % | 7.81 | 7.81 | 7.81 | 7.81 | 7.81 | 7.81 | 7.81 | 7.81 | 7.81 | 7.81 |
| EBITAT | 5,310.0 | 6,334.4 | 4,544.4 | 3,975.9 | 4,375.6 | 4,653.8 | 4,675.7 | 4,697.7 | 4,719.8 | 4,742.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -357.8 | 3,380.1 | 5,014.3 | 637.2 | 5,595.3 | 3,965.4 | 4,014.4 | 4,033.3 | 4,052.3 | 4,071.3 |
| WACC, % | 5.33 | 5.33 | 5.33 | 5.33 | 5.33 | 5.33 | 5.33 | 5.33 | 5.33 | 5.33 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 17,267.7 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | 4,234 | |||||||||
| Terminal Value | 318,653 | |||||||||
| Present Terminal Value | 245,801 | |||||||||
| Enterprise Value | 263,068 | |||||||||
| Net Debt | -20,671 | |||||||||
| Equity Value | 283,739 | |||||||||
| Diluted Shares Outstanding, MM | 6,327 | |||||||||
| Equity Value Per Share | 44.84 |
What You Will Receive
- Authentic Hengrui Financials: Access historical and projected data for precise valuation of Jiangsu Hengrui Medicine Co., Ltd. (600276SS).
- Customizable Inputs: Adjust parameters like WACC, tax rates, revenue growth, and capital expenditures to fit your analysis.
- Real-Time Calculations: Intrinsic value and NPV are calculated automatically as you make changes.
- Scenario Testing: Evaluate various scenarios to assess the future performance of Jiangsu Hengrui Medicine Co., Ltd. (600276SS).
- User-Friendly Interface: Designed for industry professionals while remaining approachable for newcomers.
Key Features
- 🔍 Real-Life Hengrui Financials: Pre-loaded historical and projected data for Jiangsu Hengrui Medicine Co., Ltd. (600276SS).
- ✏️ Fully Customizable Inputs: Modify all essential parameters (yellow cells) such as WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Integrated formulas calculate the intrinsic value of Hengrui using the Discounted Cash Flow method.
- ⚡ Instant Results: View Hengrui’s valuation instantly after making adjustments.
- Scenario Analysis: Evaluate and compare results for different financial assumptions side-by-side.
How It Works
- Download: Get the ready-to-use Excel file featuring Jiangsu Hengrui Medicine Co., Ltd.'s (600276SS) financial data.
- Customize: Modify forecasts such as revenue growth, EBITDA %, and WACC as per your requirements.
- Update Automatically: Watch intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various projections and instantly compare the results.
- Make Decisions: Leverage the valuation outcomes to inform your investment strategy.
Why Opt for Jiangsu Hengrui Medicine Co., Ltd. (600276SS)?
- Time Efficiency: Skip the hassle of building a complex financial model – it’s readily available for your use.
- Enhanced Precision: Dependable financial metrics and calculations minimize valuation errors.
- Completely Adaptable: Adjust the model to align with your specific assumptions and forecasts.
- User-Friendly: Intuitive charts and outputs make it simple to interpret the results.
- Preferred by Professionals: Crafted for those who prioritize accuracy and functionality in their tools.
Who Should Benefit from This Product?
- Institutional Investors: Develop comprehensive and accurate valuation models for investment analysis in Jiangsu Hengrui Medicine Co., Ltd. (600276SS).
- Corporate Finance Departments: Assess valuation scenarios to inform strategic decisions within their organizations.
- Financial Consultants and Advisors: Equip clients with precise valuation insights for Jiangsu Hengrui Medicine Co., Ltd. (600276SS) stock.
- Students and Academics: Leverage real-world data to enhance skills in financial modeling and analysis.
- Pharmaceutical Industry Enthusiasts: Gain insights into how companies like Jiangsu Hengrui Medicine Co., Ltd. (600276SS) are valued in the market.
Contents of the Template
- Operating and Balance Sheet Data: Pre-filled historical data and forecasts for Jiangsu Hengrui Medicine Co., Ltd. (600276SS), including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A separate sheet dedicated to the Weighted Average Cost of Capital (WACC), incorporating factors such as Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Customizable Discounted Cash Flow models illustrating intrinsic value with comprehensive calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to facilitate in-depth analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios specific to Jiangsu Hengrui Medicine Co., Ltd. (600276SS).
- Dashboard and Charts: Visual representation of valuation results and assumptions for straightforward analysis.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.